




PHARMACEUTICAL 2020

REGENERX BIOPHARMACEUTICALS INC Rank 331 of 358





PHARMACEUTICAL 2020

REGENERX BIOPHARMACEUTICALS INC Rank 331 of 358

The relative strengths and weaknesses of REGENERX BIOPHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REGENERX BIOPHARMACEUTICALS INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 35% points. The greatest weakness of REGENERX BIOPHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 128% points.

The company's Economic Capital Ratio, given in the ranking table, is -289%, being 325% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	682
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	242
Liabilities, Non-Current	2,101
Other Assets	30
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	708
Other Net Income	-142
Other Revenues	77
Property and Equipment	0
Research and Development	65
Selling, General and Administrative Expense	1,274

Output Variable	Value in 1000 USD
Assets	712
Liabilities	3,052
Expenses	1,339
Revenues	77
Stockholders Equity	-2,340
Net Income	-1,404
Comprehensive Net Income	-1,404
Economic Capital Ratio	-289%